Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MXCT

MaxCyte, Inc.

Healthcare | Medical - Devices

No licensed closing price on file for MXCT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.32

MaxCyte, Inc. (NASDAQ: MXCT) is a medical device company. Figures from SEC EDGAR; updated 2026-10-20 01:50 UTC.

What MaxCyte, Inc. does

The company is a commercial cell engineering firm that develops and sells Flow Electroporation technology, a platform used by biopharmaceutical companies to introduce molecules into cells for therapeutic and research purposes. The company's ExPERT platform includes multiple instruments and related consumables designed to support cell therapy development from discovery through commercialization. The firm serves a customer base spanning major pharmaceutical companies, biotechnology firms, and academic institutions, with technology that has been used in FDA-approved cell therapies.

Summarized from MaxCyte, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.32

Revenue, margins & earnings

FY2021: net loss $19M on revenue $34M$34MFY2021FY2022: net loss $24M on revenue $44M$44MFY2022FY2023: net loss $38M on revenue $41M$41MFY2023FY2024: net loss $41M on revenue $39M$39MFY2024FY2025: net loss $45M on revenue $33M$33MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-06-22
Most recent filed transactions — June 2026:
  • 2026-06-22DirectorStock Option (right to buy)Award49,579—
  • 2026-06-22DirectorAward30,421—
  • 2026-06-22DirectorStock Option (right to buy)Award49,579—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does MaxCyte, Inc. do?

The company is a commercial cell engineering firm that develops and sells Flow Electroporation technology, a platform used by biopharmaceutical companies to introduce molecules into cells for therapeutic and research purposes.

When did MXCT last file with the SEC?

MaxCyte, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-17. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:50 UTC. This page is also available as JSON at /api/data?ticker=MXCT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MXCT and 5,000+ tickers.

Create a free account — keep MXCT
For your agent
GET /api/data?ticker=MXCT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt